|
|
Volumn 36, Issue 3, 2002, Pages 309-311
|
|
Second-line chemotherapy for non-small cell lung cancer: Is more better or just simply more?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
CISPLATIN;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEMCITABINE;
IFOSFAMIDE;
LACTATE DEHYDROGENASE;
LONAFARNIB;
NAVELBINE;
PEMETREXED;
PLATINUM;
PROTEIN INHIBITOR;
ADJUVANT CHEMOTHERAPY;
ADVANCED CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GRADING;
CANCER MORTALITY;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER SURVIVAL;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DISEASE COURSE;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG COST;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
EDITORIAL;
FEBRILE NEUTROPENIA;
HEALTH CARE COST;
HUMAN;
LUNG NON SMALL CELL CANCER;
MONOTHERAPY;
PERFORMANCE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
TOXICITY;
TREATMENT OUTCOME;
WEIGHT REDUCTION;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS;
HUMANS;
LUNG NEOPLASMS;
PACLITAXEL;
TAXOIDS;
|
|
EID: 0036247941
PISSN: 01695002
EISSN: None
Source Type: Journal
DOI: 10.1016/S0169-5002(02)00024-7 Document Type: Editorial |
|
Times cited : (3)
|
|
References (14)
|
